Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Constellation Pharmaceuticals (CNST) PT Raised to $55 at Oppenheimer
December 9, 2019 4:21 PM ESTOppenheimer analyst Silvan Tuerkcan raised the price target on Constellation Pharmaceuticals (NASDAQ: CNST) to $55.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "CNST updated CPI-0610 data with efficacy stable in the key first-line (1L) population (n=15) and excellent tolerability in all settings. SVR35... More
